Manufacturer Roche Laboratories, Inc. should update Tamiflu labeling to include stronger warnings regarding the risk of psychiatric problems in users of the flu medicine, according to a U.S. Food and Drug Administration (FDA) committee. The FDA Pediatric Advisory Committee made its recommendations after evaluating reports of adverse events associated with use of the prescription influenza medication -- including delusions, confusion, and self-injury -- especially in children. The New York Times reports that "nearly 600 cases of psychiatric problems in Tamiflu patients have been reported, with 75 percent of them from Japan."
- FDA Information Page: Tamiflu
- NY Times: Panel Seeks New Warning on Flu Drug
- Tamiflu Side Effects and Safety (Roche Laboratories, Inc.)
- Tamiflu Information and Resources (FindLaw)